GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nirvana Life Sciences Inc (XCNQ:NIRV) » Definitions » EV-to-FCF

Nirvana Life Sciences (XCNQ:NIRV) EV-to-FCF : -7.74 (As of May. 27, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Nirvana Life Sciences EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Nirvana Life Sciences's Enterprise Value is C$1.95 Mil. Nirvana Life Sciences's Free Cash Flow for the trailing twelve months (TTM) ended in Jan. 2024 was C$-0.25 Mil. Therefore, Nirvana Life Sciences's EV-to-FCF for today is -7.74.

The historical rank and industry rank for Nirvana Life Sciences's EV-to-FCF or its related term are showing as below:

XCNQ:NIRV' s EV-to-FCF Range Over the Past 10 Years
Min: -15.07   Med: 0   Max: 0
Current: -7.74

XCNQ:NIRV's EV-to-FCF is ranked worse than
100% of 369 companies
in the Biotechnology industry
Industry Median: 8.9 vs XCNQ:NIRV: -7.74

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-27), Nirvana Life Sciences's stock price is C$0.04. Nirvana Life Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jan. 2024 was C$-0.033. Therefore, Nirvana Life Sciences's PE Ratio for today is At Loss.


Nirvana Life Sciences EV-to-FCF Historical Data

The historical data trend for Nirvana Life Sciences's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nirvana Life Sciences EV-to-FCF Chart

Nirvana Life Sciences Annual Data
Trend Oct18 Oct19 Oct20 Oct21 Apr22 Apr23
EV-to-FCF
Get a 7-Day Free Trial - - - -38.34 -3.20

Nirvana Life Sciences Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -15.06 -3.20 -5.24 -7.20 -8.68

Competitive Comparison of Nirvana Life Sciences's EV-to-FCF

For the Biotechnology subindustry, Nirvana Life Sciences's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nirvana Life Sciences's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nirvana Life Sciences's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Nirvana Life Sciences's EV-to-FCF falls into.



Nirvana Life Sciences EV-to-FCF Calculation

Nirvana Life Sciences's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=1.950/-0.252
=-7.74

Nirvana Life Sciences's current Enterprise Value is C$1.95 Mil.
Nirvana Life Sciences's Free Cash Flow for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.25 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nirvana Life Sciences  (XCNQ:NIRV) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Nirvana Life Sciences's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.04/-0.033
=At Loss

Nirvana Life Sciences's share price for today is C$0.04.
Nirvana Life Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.033.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Nirvana Life Sciences EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Nirvana Life Sciences's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Nirvana Life Sciences (XCNQ:NIRV) Business Description

Traded in Other Exchanges
N/A
Address
650 West Georgia Street, Suite 2110, Vancouver, BC, CAN, V6B 4N8
Nirvana Life Sciences Inc is focused on developing medical products and regimens that address addiction. The company is working on novel formulations of psilocybin and other naturally-sourced psychedelics to treat pain, opioid dependency, and other health problems.

Nirvana Life Sciences (XCNQ:NIRV) Headlines

No Headlines